Subtype
Bladder Carcinoma
CI-CAN-00007316Explore in graph →
141 active trials7 approved drugs19 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00007316Explore in graph →
Clinical trials
332 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (49)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04724928 | Evaluating the Impact of 18F-FDG-PET-CT on Risk Stratification and Treatment Adaptation for Patients with Muscle Invasive Bladder Cancer(EFFORT-MIBC) | recruiting | Phase 2 | 156 | University Hospital, GhentOTHER | 1 | Jan 15, 2025 | clinicaltrials |
| NCT06186414 | A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SIM0237 Alone or in Combination with BCG in NMIBC | recruiting | Phase 1 | 152 | Jiangsu Simcere Pharmaceutical Co., Ltd.INDUSTRY |
| 1 |
| Jan 15, 2025 |
| clinicaltrials |
| NCT05790850 | Pre-Habilitation with Mindfulness and Exercise for Patients Undergoing Radical Cystectomy (PRIMER Trial)(PRIMER) | recruiting | N/A | 30 | University of VirginiaOTHER | 1 | Dec 16, 2024 | clinicaltrials |
| NCT06341400 | RC48 Combined with Toripalimab As Neoadjuvant Therapy for Cisplatin Ineligible MIBC Patients | recruiting | Phase 1 / Phase 2 | 55 | Zhujiang HospitalOTHER | 1 | Dec 4, 2024 | clinicaltrials |
| NCT04167631 | Can VI-RADS/ADC Accurately Stage Bladder Cancer?? | active not recruiting | N/A | 150 | Mansoura UniversityOTHER | 1 | Oct 30, 2024 | clinicaltrials |
| NCT05215574 | Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors | active not recruiting | Phase 1 | 130 | NGM Biopharmaceuticals, IncINDUSTRY | 1 | Oct 10, 2024 | clinicaltrials |
| NCT06630871 | A Clinical Trial Evaluating the Efficacy and Safety of Disitamab Vedotin Plus Tislelizumab Combined with Re-TURBT in the Treatment of HER-2-high Expression(2+-3+) Non-muscle Invasive Bladder Cancer At High-risk and Very High-risk. | not yet recruiting | Phase 2 | 40 | Fujian Medical University Union HospitalOTHER | 1 | Oct 10, 2024 | clinicaltrials |
| NCT05203913 | Cisplatin, Nab-paclitaxel, Nivolumab With Radiotherapy After Resection of Non-Metastatic Muscle Invasive Bladder Cancer(CNN-BC) | recruiting | Phase 2 | 32 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Oct 4, 2024 | clinicaltrials |
| NCT06588179 | SHR-1501 Combined With SHR-2005 for High-Risk Non-Muscle Invasive Bladder Cancer Which is Not Completely Resectable by TURBt | not yet recruiting | Phase 1 / Phase 2 | 58 | Fudan UniversityOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06528483 | Bladder Preservation With Sacituzumab Govitecan + Zimberelimab for Muscle-Invasive Bladder Cancer(preSAVE) | not yet recruiting | Phase 2 | 63 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Jul 30, 2024 | clinicaltrials |
| NCT06325423 | Predicting Response to Neoadjuvant Chemotherapy in Muscle-invasive Bladder Cancer | not yet recruiting | — | 50 | Assiut UniversityOTHER | 0 | Mar 26, 2024 | clinicaltrials |
| NCT06170177 | Study on the Quality of Life and Pathological State in Patients Who Underwent Radical Cystectomy | recruiting | — | 4,000 | IRCCS San RaffaeleOTHER | 1 | Dec 14, 2023 | clinicaltrials |
| NCT06167356 | Study on the Occurrence of Possible Relapses and on the Quality of Life in Patients Who Underwent TURBK. | recruiting | — | 20,000 | IRCCS San RaffaeleOTHER | 1 | Dec 12, 2023 | clinicaltrials |
| NCT03379909 | Phase II Study of Oral Metformin for Intravesical Treatment of Non-muscle-invasive Bladder Cancer(TROJAN) | recruiting | Phase 2 | 49 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)OTHER | 1 | Sep 21, 2023 | clinicaltrials |
| NCT05943379 | RC48-ADC in Combination With Gemcitabine in High Risk NMIBC Subjects | recruiting | Phase 2 | 85 | RemeGen Co., Ltd.INDUSTRY | 1 | Jul 13, 2023 | clinicaltrials |
| NCT04900558 | Robotic Radical Cystectomy Outcomes | recruiting | — | 500 | University of FlorenceOTHER | 1 | May 25, 2021 | clinicaltrials |
Data updated 22 days agoSource updated Jan 15, 2025source: clinicaltrials